Femasys Inc. (FEMY), a biomedical company focused on women's health, announced on Thursday that it has received notices of intention to grant two new European patents for its FemBloc permanent birth control technology.
The new patents expand coverage for two essential components of FemBloc for fallopian tube occlusion, resulting in non-surgical permanent contraception, with anticipated expirations in 2038 and 2039.
The new patent issuance further strengthens Femasys' intellectual property portfolio, including its other innovative products such as FemaSeed, FemVue, FemCath, and FemCerv.
Femasys CEO Kathy Lee-Sepsick emphasized that the patents' approval marks a key milestone for FemBloc, positioning it as a revolutionary option for women seeking permanent birth control.
The company is currently enrolling participants in its pivotal clinical trial for U.S. approval, with previous clinical trials showing FemBloc's safety and efficacy compared to traditional surgical methods.
The patents granted by the EPO bring Femasys closer to making FemBloc available to women globally, addressing an unmet need for safer, more accessible permanent contraception.
FEMY closed Wednesday's (Jan.29 2025) trading at $1.17 up by 11.96%. In premarket trading Thursday the stock is up 0.75% at $1.17.
For comments and feedback: editorial@rttnews.com